Public Companies
2022 End of Year Review: Small Pharma
The article 2022 End of Year Review: Small Pharma was originally published on Microdose.
Continuing our end-of-year review, we’ll take a moment to update…
The article 2022 End of Year Review: Small Pharma was originally published on Microdose.
Continuing our end-of-year review, we’ll take a moment to update Small Pharma’s last 12 months.
Last week, we reported that DMT-development firm Small Pharma had moved its lead candidate drug further through the clinical trial process with the completion of its Phase 2a trial. Small Pharma CEO says that results from this Phase 2a trial will be released in early Q1 — a significant milestone for the company and the industry.
Despite Small Pharma being a relatively, hmmm, small firm, the completion of a Phase 2a trial makes them one of the most advanced companies in terms of clinical trial development. From CEO George Tziras:
We look forward to sharing the SPL026 Phase IIa results very soon, as well as making progress throughout the year with additional SPL026 trials, and the first-in-human trial with SPL028, our novel deuterated DMT candidate.
In line with this significant progress across our portfolio, we look forward to continuing to expand internationally and growing our team as we prepare for a multi-site Phase IIb trial.
Some other highlights from Small Pharma in 2022:
- Completion of Phase IIa trial for lead product candidate SPL026, with supportive therapy for the treatment of Major Depressive Disorder
- SSRI drug interaction study initiated
- MHRA approval for new SPL026 trial
- Cash on hand as of August 31, 2022, was $27.1 million
- 2nd US patent granted for DMT products, the twelfth granted patent in its psychedelic and non-psychedelic portfolio, with over 70 pending applications)
- Received approval for Phase I Clinical Trial with SPL028, injectable deuterated DMT candidate with multi-layered IP protection
For more on Small Pharma, see the company’s video below and Small Pharma Gets Big Price Target From Two Analysts
dmt psychedelic therapy major depressive disorder depressive disorder small pharma
-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Psychedelics1 week ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics1 week ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Psychedelics1 week ago
The Onion Pokes Fun at Psychedelics
-
Law & Regulation1 week ago
Compass Pathways keeps plugging away with its psilocybin study trials
-
Psilocybin1 week ago
Oregon authorities give Kaya Holdings license for psilocybin treatment clinic